The stroke-related cost of underuse of atrial flutter (AF) thromboprophylaxis is more than $8 billion. 1 Yet there continues to be widespread underutilization or, at times, inappropriate use of thromboprophylaxis. Partly responsible is the complex interplay of treatments, risks, and benefits along with variability in patient adherence and health literacy. The decision has been further complicated by the introduction of direct oral anticoagulants (DOACs). In 2011, we posited that a new generation of anticoagulants with improved safety and similar, if not improved, efficacy compared with warfarin would change the "tipping point" in the balance between risk and benefit for anticoagulation therapy. 2 By tipping point, we mean the threshold of stroke risk below which the bleeding risks of anticoagulant therapy do not result in a net clinical gain and above which the benefits of stroke prevention outweigh the risks and consequences of major bleeding.
Although recent guidelines from the American College of Chest Physicians 3 and the American Heart Association/ American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) 4 recommend that antithrombotic therapy be individualized to consider balance between risk of stroke and risk of major bleeding with treatment, bleeding risk is not explicitly considered in a quantitative manner. In short, the AHA/ACC/HRS guidelines, which now use the CHA 2 DS 2 VASc a, 5 to quantitate stroke risk, state that it is reasonable to omit antithrombotic therapy for patients with a CHA 2 DS 2 VASc of 0, consider no antithrombotic therapy or treatment with an oral anticoagulant or aspirin for patients with a CHA 2 DS 2 VASc of 1, and recommend oral anticoagulants for patients with a CHA 2 DS 2 VASc ≥ 2. The guidelines suggest using the HAS-BLED b, 6 score to quantitate risk of major bleeding while receiving oral anticoagulant therapy (OAT; warfarin or DOACs) but do not make explicit recommendations about how to integrate this into decision making.
We have previously described a computerized decision support tool that incorporates individual patient's risk factor profiles for AF-related stroke and major bleeding. 7, 8 Patient-level treatment recommendations are generated based upon projections for quality-adjusted life years (QALYs) calculated by a 29-state Markov decision analytic model. The previously described Atrial Fibrillation Decision Support Tool (AFDST) considered choices between OAT with warfarin, aspirin, or no antithrombotic therapy. We now describe an updated version of the AFDST that incorporates the DOACs dabigatran, apixaban, rivaroxaban, and edoxaban as additional strategies for thromboprophylaxis. The goal of this study was to examine the impact of DOACs on the tipping point in a real-world AF cohort in our University of Cincinnati (UC) Health system.
Methods
This study was undertaken in a single tertiary center. Our Institutional Review Board approved the study protocol.
Patient population
A total of 5,121 unique adult patients (≥21 years of age) with nonvalvular AF in the UC Health system were identified using appropriate International Classification of Diseases, 10th Revision, codes (I48.x) from the active problem lists for ambulatory visits and inpatient hospitalizations over the 1-year period (January through December 2016). Exclusion criteria include valvular heart disease (mitral valve disease [I05.x], aortic valve disease [I06.x], mitral and aortic valve disease [I08.x]), presence of prosthetic heart valve (Z95.2), presence of xenogenic heart valve (Z95.3), or presence of other heart valve replacement (Z95.4).
Atrial Fibrillation Decision Support Tool
With the increasingly widespread adoption of electronic health records (EHRs), we have platforms at the point of care in which we can embed tools that "pull" data from the EHR and then "push" recommendations out as decision support. We have developed an AFDST that uses a decision analytic engine to generate patient-level recommendations for thromboprophylaxis. [7] [8] [9] [10] Information required to calculate AF-related stroke risk using the CHA 2 DS 2 VASc, 11 major hemorrhage using HAS-BLED, 12 and intracerebral hemorrhage (ICH) 12 rates is extracted from our Epic clinical data store (Clarity) and fed to the decision analytic engine. Stroke risk and bleeding risk (extracranial and intracerebral) are modified by appropriate measures of efficacy and relative hazards for each treatment based upon evidence in the published literature. Time in therapeutic range needed to calculate the HAS-BLED score is determined by interpolating international normalized ratio values over the past year, similar to the method by Rosendaal et al. 13 We retrieved current antithrombotic therapy from the active medication list.
The current version of the AFDST is an external Web application that clinicians access by clicking on an activity button in the patient's EHR. An AF data-mart consisting of a set of relevant Clarity tables is refreshed every 24 hours. All patients in our system with a diagnosis of nonvalvular AF are in the data-mart. Treatment recommendations are generated based upon projections for QALYs calculated by the decision analytic model.
The computational engine of the AFDST is a 29-state Markov state transition model examining strategies of (1) no antithrombotic therapy, (2) aspirin, (3) warfarin, (4) dabigatran, (5) apixaban, (6) rivaroxaban, and (7) edoxaban (Appendix Figure 1) . The AFDST uses population-based utilities to value quality of life for health states in the model. We developed the model using a standard computer program (Decision Maker, Boston, MA) for model construction and analysis.
Efficacy of treatment and relative risk of complications including major bleeding and ICH were informed by literature review including meta-analyses 14, 15 and network meta-analyses [16] [17] [18] of DOACs in general populations and in the elderly 19, 20 along with systematic reviews given the absence of head-to-head trials comparing DOACs to one another. 16, 17 Logic was included to avoid recommending DOACs in patients with advanced chronic kidney disease. None of the DOACs were considered alternative treatments to warfarin or aspirin if the estimated glomerular filtration rate (eGFR) was b30 mL/min/1.73 m 2 . Edoxaban was not considered if eGFR was N95 mL/min/1.73 m 2 . To evaluate the impact of DOACs, we analyzed model recommendations for all 5,121 members of our UC Health AF cohort using structured query language to generate a batch file containing all necessary values for clinical and demographic parameters. We then used Decision Maker's remote control function to run a script file containing patient-level information through the decision analytic model. Results were stored to a text file that was loaded into a structured query language database. The AFDST recommends the strategy resulting in the largest expected utility in QALYs. We used 0.1 QALY as a minimal clinically significant gain to consider one strategy better than another.
Review of data
Risk of ischemic stroke. We used the CHA 2 DS 2 VASc score to calculate the risk of AF-related stroke without treatment (Appendix Table I ). 5 Although there are several mappings of stroke risk for any given CHA 2 DS 2 VASc score, we used rates from the SPORTIF III and V trials to be consistent with the rates quoted in the AHA/ACC/HRS guidelines. [21] [22] [23] Efficacy of thromboprophylactic treatment. In each strategy, the risk of AF-related stroke was modified by the efficacy of treatment. We used a declining efficacy for aspirin with increasing age, such that efficacy is zero for patients ≥77 years of age, based on an analysis of the AF Investigators database of 8,932 patients and 17,685 years of observation. 24 We used an efficacy of 0.68 for warfarin 25 and adjusted for the efficacy of the DOACs by multiplying risk ratios determined in a network meta-analysis 18 times the monthly probability of AF-related stroke while taking warfarin (Table I) . If the risk ratios were not statistically significant, we used a risk ratio of 1.0. We explored this assumption in sensitivity analyses ("Results").
Risk of major bleeding. We used the HAS-BLED score to calculate the risk of major extracranial bleeding while receiving warfarin (Appendix Table II ). We calculated the annual rate of major extracranial bleeding without warfarin by dividing the HAS-BLED-calculated rate by 2.4, the relative hazard of major bleeding while taking warfarin (Table I) . 26 The risk of major extracranial bleeding while receiving aspirin was 1.08 times the rate off treatment. 26 The monthly probability of major extracranial bleeding while receiving treatment with DOACs was calculated by multiplying a risk ratio for each agent times the monthly probability of bleeding while receiving warfarin. 18 In the case of dabigatran, we used evidence from a meta-analysis describing an increasing hazard of major bleeding relative to warfarin as age increased.
Risk of intracerebral bleeding. We independently modeled the risk of ICH in untreated patients based on a multivariate regression model developed on a Swedish registry population of 90,490 untreated patients with AF. 12 We calculated the annual rate of ICH while receiving warfarin by multiplying this base rate times 4.1, 27, 28 whereas that of aspirin-treated patients was 1.84 times that of untreated patients (Table I) . [29] [30] [31] Annual rates of ICH while receiving treatment with DOACs were calculated by multiplying the annual ICH rate of warfarin-treated patients times a relative risk for each DOAC. 18 Annual mortality from nonexplicitly modeled causes. Annual mortality from nonexplicitly modeled causes was based on the most recent life tables available from the Centers for Disease Control (2011 data, obtained in 2016) specific to age and gender. 32 In addition, patients faced an excess mortality risk for major comorbidities known from our collection of CHA 2 DS 2 VASc and HAS-BLED risk factors. These included type 2 diabetes, hypertension, congestive heart failure, chronic kidney disease, and prior cerebral vascular accident (Table I) .
Role of the funding source
The study was funded by the Heart Rhythm Society through a grant from Boehinger-Ingelheim Pharmaceuticals, Inc (BIPI) to Dr Eckman. It was also supported by the National Center for Advancing Translational Sciences (National Institutes of Health UL1TR000077-05). The funding sources had no role in study design, data collection, data analysis, data interpretation, or writing of the manuscript. BIPI was given the opportunity to review the manuscript for medical and scientific accuracy as it relates to BIPI substances, as well as intellectual property considerations. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. The authors are solely responsible for the design and conduct of this study, all study analyses, and the drafting and editing of the paper.
Results
Patient characteristics are summarized in Table II . Our AF cohort has significant comorbid diseases as reflected by mean CHA 2 DS 2 VASc and HAS-BLED scores of 3.5 and 2.4, respectively. A sample AFDST report is shown in Figure 1 . For many patients, the results do not favor a clear best treatment among DOACs, as they have similar efficacies and risks. From a decision analytic perspective, they are all reasonable choices. Therefore, the best choice for these patients must also include factors that are more subjective. We based these on our previous work assessing factors beyond treatment efficacy and life-threatening adverse effects that patients feel are important in decision making. These include out-of-pocket cost, frequency of administration, reversal agents, need to take with food, significant nonlife-threatening adverse effects (such as dyspepsia), complexity of food-drug or drug-drug interactions, and need to have blood work done on a recurring basis (eg, once-or twice-monthly visits for international normalized ratio [INR] ). Appendix Figure 2 shows medication cards we developed to compare and contrast these more subjective issues (see Appendix Figures 3-4 for full patient-specific report).
Across the cohort of 5,121 AF patients, the AFDST recommended OAT (warfarin or one of the DOACs) for 4,134 (81%) patients and no antithrombotic therapy or aspirin for 489 (9%). For 498 patients (10%), the gain afforded by any form of thromboprophylaxis (compared with no treatment) was less than 0.1 QALY; thus, no firm recommendation was given for these patients (ie, decision was a "toss-up" between the best OAT and no antithrombotic therapy). We next compared AFDST recommendations to current treatment. As shown in Figure 2 , A along the descending diagonal, current treatment is concordant 25, 40 With severe disability 0.69 25, 40 With mild disability 0.31 25, 40 Good recovery 0.40 25, 40 15 was recommended for 144 patients (30%) who are currently receiving OAT, resulting in an estimated loss of 113 QALYs due to potentially unnecessary thromboprophylaxis. In total, 1,508 QALYs could be gained if treatment were changed to that recommended by the AFDST.
To appreciate the impact of DOACs on the tipping point, we also explored results assuming that DOACs were not available and warfarin was the only option for oral anticoagulation. In this scenario, the AFDST recommended OAT for 3,228 (63%) patients and no antithrombotic therapy or aspirin for 973 (19%) patients. For 920 patients (18%), the gain afforded by any form of thromboprophylaxis was less than 0.1 QALY. We next compared AFDST recommendations to current treatment. As shown in Figure 2 , B along the descending diagonal, current treatment is concordant with recommendations for 1,921 patients currently receiving OAT and for 584 patients receiving either aspirin or no thromboprophylaxis. The AFDST recommended OAT for 1,307 patients who currently are not receiving such treatment. Anticoagulant therapy for these patients could result in an estimated aggregate gain of 733 QALYs. No thromboprophylaxis (234) or aspirin (155) was recommended for 389 patients who are currently receiving OAT, resulting in an estimated loss of 176 QALYs due to potentially unnecessary thromboprophylaxis. In total, 909 QALYs could potentially be gained if treatment were changed to that recommended by the AFDST.
Of note, eGRF was b30 mL/min/1.73 m 2 in 356 patients (7%) of the 4,802 for whom we had data on renal function. As a result, treatment with any of the DOACs was not considered as an option for these patients. We performed a sensitivity analysis in which we allowed use of DOACs for patients with eGFRs between 15 and 30 mL/min/1.73 m 2 . We assumed that efficacy and bleeding risk were the same despite renal dose adjustments. This had minimal impact on the overall proportion of patients recommended for anticoagulant therapy, 4,187 (82%) compared with 4,134 (81%) in the base-case analysis, or CVA, cerebral vascular event including ischemic stroke or ICH. ⁎ Assume outcomes of bleeding events for aspirin-treated patients are the same as for untreated patients. † Poorly controlled hypertension: systolic blood pressure ≥160 mm Hg. ‡ Duration of short-term utility loss for major extracranial bleed is 12 months. § Excess annual mortality rates added to age-and gender-adjusted annual mortality rates (μASR). ‖ Multiply relative hazard times age and gender-adjusted μASR.
on the net gain in QALYs if treatment were changed to that recommended by the AFDST (1,521: base case vs 1,508: sensitivity analysis).
In our base-case analysis, we used risk ratios of 1 for ischemic stroke and major bleeding risk when confidence limits crossed 1 in the network meta-analysis. 18 We performed a sensitivity analysis on these assumptions using relative risks of ischemic stroke of 0.96 and 0.94 for apixaban and rivaroxaban, respectively, compared with warfarin and a relative risk of major bleeding of 1.03 for rivaroxaban compared with warfarin. Results of this sensitivity analysis showed little change in either the proportion of patients for whom anticoagulant therapy was recommended, 4,175 (82%), or on the net gain in QALYs if treatment were changed to that recommended by the AFDST (1,517) .
Finally, we wished to explore the magnitude of the gain or loss with OAT compared with no thromboprophylaxis across CHA 2 DS 2 VASc and HAS-BLED scores. Appendix Figure 5 shows the joint distribution of these 2 measures in our cohort. There is a clear correlation between these scores, highlighting the clinical challenge-as AF-related stroke risk increases, for many patients, the risk of major bleeding while receiving OAT also increases. Most Sample report from AFDST. Screen shot of report that appears in Epic Hyperspace frame when AFDSM is launched from a patient's chart. Red, bolded items indicate clinical risk factors extracted from the AF data-mart used to predict the patient's risk of stroke, major bleeding, intracranial bleeding, and QALYs for each of the considered treatments. In this example, the patient is an 80-year-old woman with a history of hypertension and type 2 diabetes. Her most recent eGFR is 70 mL/min/1.73 m 2 . Her HAS-BLED is 1 and her CHA 2 DS 2 VASc score is 5. Her annual rate of ischemic stroke without thromboprophylaxis is 6.7%. Her annual rate of major non-central nervous system bleeding while taking warfarin is 0.7%. This is an upper limit on risk of major bleeding, as the relative hazard of major bleeding is less than 1 for several of the DOACs. A separate model predicts the annual rate of ICH while taking warfarin, 0.29% for this patient. This also is an upper limit, as the relative hazard of ICH is less than 1 for all of the DOACs. The graphic to the far right indicates gain or loss in QALYs for each of the considered strategies compared with no treatment. The visual analog scale is divided into 3 regions: green, indicating a clinically significant gain; red, indicating a clinically significant loss; and yellow, indicating a gain or loss less than 0.1 QALY, which makes treatment too close to call as a recommended strategy compared with no treatment. For this patient, aspirin provides no benefit, whereas warfarin and the 4 DOACs all fall in the green range, providing net gains of 0.72 to 0.97 QALY compared with no treatment. In particular, dabigatran, apixaban, and edoxaban all fall within 0.1 QALY of each other, making them indistinguishable from a decision analytic perspective. In this example, all of the oral anticoagulants are reasonable choices. The patient's decision between these agents needs to be guided by other more nuanced factors such as out-of-pocket cost, availability of reversal agent, number of doses per day, need for routine laboratory testing, and others. The clinician can click on the tab labeled "Print" to give the patient a copy of the report to take home. To facilitate this discussion in a typical shared decision-making encounter, the clinician would next click on the tab at the far right of the top ribbon, labeled "Anticoagulant Medication Details." A graphic of medication cards (Appendix Figure 2) detailing these factors that are important for patient choices between the various recommended oral anticoagulants appears, continuing to support the shared decisionmaking discussion.
patients lie along a diagonal emanating from the upper left of the figure. Figure 3 shows the aggregate population gain or loss in QALYs with oral anticoagulation compared with no thromboprophylaxis in each cell. Figure 3 , A describes the situation in which DOACs are available, whereas Figure 3 , B describes the situation in which only warfarin is available. In both of these figures, the greatest population gain occurs along a diagonal emanating from In the discordant cells (bottom left to top right), the lower number represents the gain or loss in QALYs between recommended and current treatment. For instance (bottom left), 119 QALYs could be gained if the 123 patients currently receiving treatment with oral anticoagulant therapy for whom the AFDST recommended either no thromboprophylaxis or aspirin were taken off oral anticoagulants. In the cell at the top right, 1,362 QALYs could be gained if these 1673 patients currently not receiving oral anticoagulant therapy were started on such treatment. In the setting of DOAC availability, an aggregate gain of 1,481 QALYs could potentially be achieved if treatment were changed to that recommended by the AFDST. B, Results of AF cohort analysis when warfarin is the only available option for oral anticoagulant therapy. In this setting, an aggregate gain of 872 QALYs could potentially be achieved if treatment were changed to that recommended by the AFDST.
the upper left. Patients with a CHA 2 DS 2 VASc score of 0 do not benefit from oral anticoagulation therapy in either scenario. When DOACs are available, significant population gains (N100 QALYs) achieved with oral anticoagulation are concentrated in the region between HAS-BLED scores of 0 and 3 and CHA 2 DS 2 VASc scores between 1 and 5. When warfarin is the only oral anticoagulant available, significant population gains (N100 QALYs) achieved with anticoagulation are concentrated in a smaller region between HAS-BLED scores of 0 and 2 and CHA 2 DS 2 VASc scores between 1 and 4.
Limitations
Our study had a number of important limitations. First, our model and analyses only considered single-agent decisions for anticoagulation in patients with AF. We did not consider situations in which dual therapy (ie, aspirin and an oral anticoagulant) or triple therapy (ie, aspirin, clopidogrel, and an oral anticoagulant) is being used, as the clinical situations are generally even more complex, including scenarios of acute coronary syndrome and/or stenting. Second, we used a broad definition to exclude AF patients with valvular heart disease, as International Classification of Diseases, 10th Revision, codes do not specify degree of stenosis or regurgitation. Thus, we excluded even patients with mild disease. Seven hundred and sixty-eight patients were excluded from our cohort for valvular heart disease or valve replacement.
Another important limitation was the use of the active problem list and the history list from the EHR as the source of diagnostic information used to inform the CHA 2 DS 2 VASc and HAS-BLED scores. It is possible that inaccurate information gets into the medical record at the level of provider data entry. To provide safeguards for this in clinical practice, the AFDST provides clinicians with the opportunity to review diagnostic information extracted from the EHR and either add or remove clinical risk factors. In a prior study of the AFDST, we found that clinicians made such changes in a total of roughly one-third of patients. 7 However, the most common change was the addition of coronary artery disease as a diagnosis not captured on our query of the active problem lists. Although such changes may have affected the magnitude of the gain or loss with OAT, it was rare that they caused the AFDST recommendation to change.
Renal dosing adjustments, based on how creatinine clearance (CrCl) was measured in clinical trials evaluating the DOACs, used CrCl calculated with the Cockcroft-Gault formula. However, as a practical matter, many electronic health record systems, including our Epic installation, provide automated calculations of CrCl using eGFR as calculated by the Chronic Kidney Disease Epidemiology Collaboration formula. 33 Studies have shown this calculation to be more accurate in assessing renal function than either the Modification of Diet in Renal Disease or the Cockcroft-Gault formula. As a result, the AFDST uses the eGFR as calculated by the Chronic Kidney Disease Epidemiology Collaboration formula as a proxy for CrCl. Third, in calculating both efficacy of the DOACs in preventing ischemic stroke, and major bleeding, when relative risks were not statistically significant (ie, confidence limits of risk ratios crossed 1), we assumed that these risks were not statistically different from warfarin. We performed sensitivity analyses to explore the impact of this assumption on our results, and it was quite small. Finally, the decision support tool we are using in our health system has been programmed to be very conservative concerning DOAC use in patients with advanced CKD. Numerous studies have documented a growing national problem with inappropriate dosing of DOACs, particularly overdosing in patients with CKD. 34, 35 This problem is compounded by the dynamic and progressive nature of CKD, and without careful monitoring of renal function and appropriate dose adjustments, patients can be exposed to excessive risks of major bleeding. Therefore, the AFDST does not recommend DOACs as an option for oral anticoagulation when the eGFR is less than 30 mL/min/1.73 m 2 even though manufacturer dosing guidelines allow for renal dosing adjustments for eGFR as low as 15 mL/min/1.73 m 2 . This is consistent with current guidelines that still suggest the avoidance of DOACs in patients with CKD stages 4-5. 3, 4 We performed sensitivity analyses to explore the impact of this assumption on results. Once more, the impact was quite small, leaving the results of our base-case analysis robust to these assumptions.
Discussion
Our analysis suggests that the tipping point has indeed changed given the introduction of a new generation of oral anticoagulants. In our study, projecting the potential aggregate net gain in QALYs in our health system's AF population, the availability of these agents, with an improved safety profile relative to major bleeding events, particularly and at least equivalent efficacy in the prevention of ischemic strokes, increased the proportion of patients for whom oral anticoagulation therapy was recommended from 63% if warfarin were the only option to 81% when DOACs are included. The availability of DOACs also increased the projected gain in QALYs, achieved by recommended treatment, by more than 1,500 versus 909 QALYs if warfarin were the only oral anticoagulant available. In addition, the range of CHA 2-DS 2 VASc and HAS-BLED score combinations (Figure 3 ) for which oral anticoagulation therapy is favored increased when DOACs were included as options for anticoagulant therapy. When examining the aggregate population gains or losses in QALYs shown in Figure 3 , it is important to note that the CHA 2 DS 2 VASc and HAS-BLED scores are not the only factors that are changing. Many other clinical parameters that affect life expectancy and quality of life are changing simultaneously, depending upon their joint distribution with risk factors in the CHA 2 DS 2 VASc and HAS-BLED algorithms. In particular, these include the annual rate of ICH for which the AFDST uses a separate prediction model, and competing forces of mortality due to chronic diseases such as diabetes, hypertension, heart failure, and chronic kidney disease. Finally, with the availability of DOACs, the proportion of patients for whom aspirin is optimal has become exceedingly small. When warfarin was the only available oral anticoagulant, the AFDST recommended aspirin for 6% of patients, whereas aspirin was recommended for only 0.5% of patients when DOACs were available.
An important issue we did not explore in this study is the possible declining risk of ischemic stroke among AF patients. 2 The AFDST uses stroke rates referenced by the AHA/ACC/HRS guidelines for the CHA 2 DS 2 VASc. [21] [22] [23] Reported stroke rates in other AF cohorts are either higher or lower for any given CHA 2 DS 2 VASc score. 36 In particular, stroke rates in ATRIA, the community-based Kaiser Permanente AF cohort, are lower for CHA 2 DS 2-VASc scores b8. 37 It is unclear whether this variation is due to differences in methodology used to assess strokes or true differences in stroke rates across populations. The consequence of lower stroke rates would be to move the tipping point in the opposite direction, decreasing the proportion of AF patients for whom OAT results in a net benefit. Ultimately, the balance of these 2 forces-the availability of oral anticoagulants with an improved safety profile and a possible declining risk of AF-related stroke-will determine the true tipping point. This has great importance for both guideline recommendations and decision support tools, such as the AFDST. What do we do in the meantime? We cannot afford to abrogate decision making for these patients and must use the best tools available. However, we must remain mindful of the variation and uncertainty that surround reported stroke rates and use guidelines and decision support tools as aids and not replacements for thoughtful decision making.
